My first "gene vaccine for the treatment of rheumatoid arthritis" won the gold medal of International Invention

Source: China Science and Technology Network - Science and technology daily, May 4, 2015, reporter learned from 307 Hospital of PLA that the project "a DNA vaccine for the treatment of rheumatoid arthritis and its use" led by Xi Yongzhi's team of Immunology Research Office of the hospital stands out from more than 1000 achievements in 48 countries and regions and won the 43rd prize Gold medal of Geneva International Invention Exhibition This is the only gold award in the field of biopharmaceutical in this invention exhibition, and also the third gold award for this project after the 8th International Invention Exhibition in 2014 and the 9th Beijing invention and innovation competition in 2015 Rheumatoid arthritis (RA) is an autoimmune disease that seriously affects the physical and mental health of human beings and causes major disability It is commonly known as "immortal cancer" Up to now, there is no root therapy Therapeutic DNA vaccine is one of the most concerned and respected new strategies It is a new strategic commanding point of global biomedical industry after antibody drugs In June 2014, the State Council decided to comprehensively promote the R & D and industrialization of therapeutic vaccines in China as a major national development strategy According to researcher Xi Yongzhi, with the support of key projects of the Ministry of science and technology of the people's Republic of China and NSFC, and after more than 20 years of unremitting efforts, he and his team took the lead in cloning the internationally recognized chicken II collagen coding gene with significant medicinal value, and developed the world's first new therapeutic gene vaccine based on the heterogeneous type II collagen gene According to the pre clinical verification, its effect is almost the same as that of the gold standard drug methotrexate (MTX), which is currently used in the treatment of RA, and it avoids the serious side effects of MTX This is an original achievement with completely independent intellectual property rights in China It has become the first project in China that simultaneously owns the gene invention patents of "the United States, the United Kingdom, France, Germany and Japan", and has been included by the Ministry of science and technology of the people's Republic of China in the major new drug creation science and technology special project in 2015.